iRadimed Corporation (IRMD) To Go Ex-Dividend on May 15th

iRadimed Corporation (NASDAQ:IRMD) announced a quarterly dividend on Thursday, April 30th. Shareholders of record on Friday, May 15th will be paid a dividend of 0.20 per share by the medical equipment provider on Friday, May 29th. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, May 15th.

iRadimed has a dividend payout ratio of 40.2% indicating that its dividend is sufficiently covered by earnings.

iRadimed Stock Performance

Shares of NASDAQ IRMD opened at $84.75 on Wednesday. iRadimed has a fifty-two week low of $50.88 and a fifty-two week high of $107.90. The company has a market cap of $1.08 billion, a PE ratio of 46.31 and a beta of 0.90. The business has a 50-day simple moving average of $94.77 and a two-hundred day simple moving average of $94.62.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts predict that iRadimed will post 1.52 earnings per share for the current fiscal year.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $101.38, for a total value of $506,900.00. Following the sale, the chief executive officer directly owned 2,242,500 shares of the company’s stock, valued at approximately $227,344,650. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 52,500 shares of company stock worth $5,030,288 in the last three months. Insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Institutional investors have recently modified their holdings of the stock. CWM LLC boosted its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. Quarry LP acquired a new position in iRadimed in the third quarter valued at approximately $40,000. Farther Finance Advisors LLC boosted its position in iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC grew its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new stake in shares of iRadimed in the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.